Systemic treatment can extend the overall survival of patients with advanced hepatocellular carcinoma (HCC). However, results vary among individuals, and the predictive factors for survival rates in advanced HCC patients are still unclear. Previous studies have shown that the patient's frailty index is related to adverse outcomes in liver cirrhosis and liver transplant recipients. It has also been confirmed to predict the results of systemic treatment in cancer patients. From September 7-9, 2023, the 17th Annual Meeting of the International Liver Cancer Association (ILCA) was grandly held in Amsterdam, the Netherlands. At this ILCA 2023 meeting, Dr. Karen W.D. Prince from the Prince Alfred Hospital in Sydney, Australia, delivered an oral report on a multicenter prospective observational study (Abstract No.: O-08), which analyzed the factors related to the mortality rate of advanced HCC patients undergoing systemic treatment. The results show that the Liver Frailty Index (LFI) can serve as an independent predictor of mortality in late-stage HCC patients undergoing systemic treatment. This journal provides a comprehensive report.
